

Curriculum Vitae

Full Name: **David M. Marks, M.D.**

Contact: **d.marks@duke.edu**
Mobile (619) 822-7117

Credentials: **Diplomate, American Board of Psychiatry and Neurology (Psychiatry)**

- **Subspecialty Certification in Psychosomatic Medicine**

Diplomate, American Board of Pain Medicine

Position Title: **Associate Professor**
Department of Psychiatry and Behavioral Sciences
Department of Community and Family Medicine
Duke University Medical Center
Duke Clinical Research Institute
Duke Pain and Palliative Care Clinic

Education:

Institution & Location	Degree	Year Conferred	Field of Study
University of California at San Diego San Diego, CA	Fellowship	1999 - 2000	Consultation and Liaison Psychiatry
Medical College of Pennsylvania / Clinical Neuroscience Research Unit Philadelphia, PA	Senior Resident	1998 - 1999	Psychiatry
University of California at San Diego San Diego, CA	Resident	1995 - 1998	Psychiatry
University of Texas Medical Branch Galveston, TX	M.D.	1995	
Rice University Houston, TX	B.A.	1991	Psychology

Research and Professional Experience:

Position	Institution/Employer & Location	Dates of Employment
Attending Faculty Physician	Duke Pain and Palliative Care Clinic (Chronic Pain Management)	09/08-present
Attending Faculty Physician	Duke University Medical Center, Inpatient Psychiatric Service, Emergency Service, Consultation/Liaison Service	07/06-present
Attending Faculty Physician	Durham Regional Hospital, Consultation/Liaison Service	09/08-07/11
Medical Director, Inpatient and Emergency Psychiatry Services	Duke University Medical Center	07/06 – 02/07
Medical Director, CNS Division	EStudy Site La Mesa, Oceanside, National City CA	05/05 -- 07/06
Chief Executive Officer/Medical Director	Optimum Health Services La Mesa, Oceanside CA	01/02 – 05/05
Chief of Staff	Alvarado Parkway Institute La Mesa, CA	01/04 – 01/05

Chief of Staff Elect	Alvarado Parkway Institute La Mesa, CA	12/02 – 12/03
Assistant Medical Director	Behavioral & Medical Research, LLC (California Clinical Trials) San Diego, CA	04/00 - 01/02
Secretary/Treasurer of Medical Executive Committee	Alvarado Parkway Institute La Mesa, CA	12/01 – 12/02
Clinical Director of Intensive- Care Unit North	Alvarado Parkway Institute La Mesa, CA	10/01 – 07/06
Associate Medical Director	Integrated Insights San Diego, CA	10/00 – 07/06
Assistant Clinical Professor/ Clinical Instructor	UCSD Department of Psychiatry San Diego, CA	07/99 – 07/06
Clinical Director of Research	Alvarado Parkway Institute La Mesa, CA	01/01 - 10/01
Medical Director	Isis Center Short-term Residential Treatment Program San Diego, CA	08/99 - 04/00
Director of Clinical Education	Integra Managed Behavioral Health Care Organization King of Prussia, PA	09/98 - 06/99
Staff Psychiatrist	Charter Fairmount Institute Philadelphia, PA	09/98 - 06/99
Staff Psychiatrist	California Psychiatric Coverage San Diego, CA	10/97 - 07/98
Staff Psychiatrist (volunteer position)	St. Vincent De Paul Village San Diego, CA	12/97 - 06/98
Instructor	Psychopathology UCSD Medical School San Diego, CA	01/97 - 05/97
Instructor	DSM-IV for the Novice Practitioner UCSD Extension San Diego, CA	04/96
Instructor	Introduction to Patient Evaluation UTMB Medical School Galveston, TX	09/94 - 05/95
Research Assistant	Psychiatric Epidemiology Laboratory, UTMB Galveston, TX	05/91 - 08/91
Research Assistant	National Institutes of Health Student Research Forum, UTMB Galveston, TX	05/92 - 08/92

Honors and Awards:

Fellowship to Explore Complementary Medicine, 1999
 Commendation for Teaching, UCSD Department of Psychiatry, 1997
 UTMB Clinical Pathology Conference Award, 1993
 National Merit Scholar, Rice University

Memberships:

American Psychiatric Association
 North Carolina Psychiatric Association

Publications:

- Marks DM** and Zisook S. "Mood Disorders" in Psychiatry: Pearls of Wisdom, Boston Medical Publishing Corporation, 1999.
- Marks DM**, Shah MJ, Patkar AA, Masand PS, Park GY, Pae CU. Serotonin-norepinephrine reuptake inhibitors for pain control: premise and promise. *Current Neuropharmacology*. 2009; 7(4):331-6.
- Marks DM**, Park MH, Ham BJ, Han C, Patkar AA, Masand PS, Pae CU. Paroxetine: safety and tolerability issues. *Expert Opinion on Drug Safety*. 2008; 7(6):783-94.
- Marks DM**, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. *Psychiatry Investigation*. 2008;5.
- Marks DM**, Pae CU, Patkar AA. Potential role of pregabalin in the treatment of lithium-induced tremor: a case report. *The International Journal of Neuropsychopharmacology* 2008; April 7.
- Marks DM**, Thanaseelan J, Pae CU. Innovations in Clinical Research Design and Conduct in Psychiatry: Shifting to Pragmatic Approaches. *Psychiatry Investigation* 2009; 6(1).
- Marks DM**, Patkar AA, Masand PS, Pae CU. Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective. *Psychiatry Investigation* 2009 June; 6(2): 55–58.
- Marks DM**, Han C, Krulewicz S, Pae CU, Peindl K, Patkar AA, Masand PS. History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome. *The Primary Care Companion to the Journal of Clinical Psychiatry* 2008;10(5).
- Marks DM**, Pae CU, Patkar AA. Triple reuptake inhibitors: the next generation of antidepressants. *Current Neuropharmacology* 2008 Dec;6(4).
- Marks DM**, Conner JM, Pae CU. Safety and antipsychotic efficacy of “forced” intramuscular olanzapine over five days: a case report. *Progress in Neuropsychopharmacology and Biological Psychiatry* 2009 Jan 6.
- Marks DM**, Abramowitz JS, Speilmans GI. Concerns about data reporting and interpretation in "Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. *Journal of Psychiatric Research* 2012 May;46(5):692-3.
- Marks DM**. Amitifadine Hydrochloride. *Drugs of the Future* 2012;37(4):241-6.
- Marks DM**, Bolognesi MP. Open-Label Milnacipran for Persistent Knee Pain One Year or Longer after Total Knee Arthroplasty (TKA). *Primary Care Companion for CNS Disorders* 2013;15(4).
- Marks DM**, Pae CU, Patkar AA. A Double-Blind, Placebo-Controlled, Parallel-Group Pilot Study of Milnacipran for Chronic Radicular Pain (Sciatica) Associated with Lumbosacral Disc Disease. *Primary Care Companion for CNS Disorders* (In press).
- Pae CU, **Marks DM**, Shah M, Han C, Ham BJ, Patkar AA, Masand PS. Milnacipran: Beyond a Role of Antidepressant. *Clinical Neuropharmacology*. 2009 Jun 10.
- Pae CU, **Marks DM**, Patkar AA, Masand PS, Luyten P, Serretti A. Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants. *Expert Opinion on Pharmacotherapy*. 2009 Jun 11.

Pae CU, **Marks DM**, Masand PS, Peindl K, Hooper-Wood C, Han C, Mannelli P, Ciccone P, Patkar AA. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. *Clinical Neuropharmacology* 2009; 32(2):85-88..

Pae CU, **Marks DM**. Does minocycline have antidepressant effect? *Biomedicine and Pharmacotherapy* 2008; Jun;62(5).

Pae CU, **Marks DM**, Han C, Patkar AA. A case of transient hallucination with ropinirole augmentation in a patient with treatment-resistant depression: is there differential effect of ropinirole dose on developing psychotic symptoms? *Progress in Neuropsychopharmacology and Biological Psychiatry*. 2008 May 15;32(4).

Pae CU, **Marks DM**, Han C, Masand PS, Patkar AA. Pregabalin augmentation of antidepressants in patients with accident-related posttraumatic stress disorder: an open-label pilot study. *The International Journal of Clinical Psychopharmacology*. 2009 Jan;24(1).

Pae CU, **Marks DM**, Han C, Patkar AA, Masand PS. Duloxetine: an emerging evidence for fibromyalgia. *Biomedicine and Pharmacotherapy*. 2008; May 2 .

Pae CU, Tharwani H, **Marks DM**, Masand PS, Patkar AA. Atypical depression: a comprehensive review. *CNS Drugs*. 2009 Dec 1;23(12):1023-37.

Pae CU, Park MH, **Marks DM**, Han C, Patkar AA, Masand PS. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. *Current Opinion Investigational Drugs* 2009 Jan;10(1).

Pae CU, Luyten P, **Marks DM**, Han C, Park MH, Patkar AA, Masand P, Van Houdenhove B. The relationship between fibromyalgia and major depressive disorder: a comprehensive review. *Current Medical Research and Opinion*. 2008;24(8).

Pae CU, Masand PS, **Marks DM**, Krulewicz S, Peindl K, Mannelli P, Patkar AA. History of depressive and/or anxiety disorders as a Predictor of Treatment Response: A Post-hoc Analysis of a 12-week, Randomized, Double-blind, Placebo-controlled Trial of Paroxetine controlled release in Patients with Fibromyalgia. *Progress in Neuropsychopharmacology and Biological Psychiatry*. 2009 May 8.

Han C, **Marks DM**, Pae CU, Lee BH, Ko YH, Masand PS, Patkar AA, Jung IK. Paroxetine for patients with undifferentiated somatoform disorder: A prospective, open-label, 8-week pilot study. *Current Therapeutic Research*. 2008;69(3).

Han C, Kwak KP, **Marks DM**, Pae CU, Wu LT, Bhatia KS, Masand PS, Patkar AA. The impact of the CONSORT statement on reporting of randomized clinical trials in psychiatry. *Contemporary Clinical Trials*. 2008 Nov 30. [Epub ahead of print]

Kim JL, Rele S, **Marks DM**, Masand PS, Yerramsetty P, Millet RA, Keefe RS, Patkar AA. Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. *Primary Care Companion for CNS Disorders*. 2013;15(6).

Pae CU, Mandelli L, Kim TS, Han C, Masand PS, **Marks DM**, Patkar AA, Steffens DC, DeRonchi D, Serretti A. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. *Biomedicine and Pharmacotherapy*. 2008; Apr 30.

Pae CU, Masand PS, Peindl K, Mannelli P, Han C, **Marks DM**, Patkar AA. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. *The Primary Care Companion to the Journal of Clinical Psychiatry*. 2008;10.

Pae CU, Han C, Masand PS, Krulewicz S, Peindl K, **Marks DM**, Patkar AA. History of depressive and anxiety disorders and treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *The Primary Care Companion to the Journal of Clinical Psychiatry* (in press).

Pae CU, **Marks DM**, Han C, Masand PS. Delirium: Where do we stand? *Current Psychiatry Report*. 2008 Jun;10(3).

Pae CU, Han C, **Marks DM**, Patkar AA, Steffens DC. Does neurotrophin-3 have a therapeutic implication in major depression? *The International Journal of Neuroscience*. 2008;118(11).

Pae CU, Masand PS, Peindl K, Mannelli P, Han C, **Marks DM**, Patkar AA. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram (Lexapro®) in patients with major depression with atypical features. *The Primary Care Companion to the Journal of Clinical Psychiatry*. 2008;10(3).

Pae CU, Han C, **Marks DM**, Patkar AA. Comments on "Addition of lamotrigine to valproic acid: A successful outcome in a case of rapid-cycling bipolar affective disorder". *Progress in Neuropsychopharmacology and Biological Psychiatry*. October 25, 2007.

Hardy TA, Henry RR, Forrester TD, Kryzhanovskaya LA, Campbell GM, **Marks DM**, Mudaliar S. Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. *Diabetes, Obesity and Metabolism* 2011. March 17 (epub ahead of print).

Oral and Poster Presentations:

Hypnoanalgesia in Clinical Practice

Annual Meeting of the Academy of Psychosomatic Medicine; New Orleans, LA. 1999.

Optimizing Treatment Outcomes in Bipolar Disorder

Grand Rounds, Alvarado Parkway Institute; La Mesa, CA. April 2, 2002.

A Randomized, Double-Blind, Placebo-Controlled Trial of Methylphenidate Extended Release (OROS MPH) in the Treatment of Antidepressant-Related Sexual Dysfunction.

Poster Presentation, American Psychiatric Association (APA) Annual Meeting; Washington DC. May 6, 2008.

New Clinical Drug Evaluation Unit (NCDEU) Meeting; May 29, 2008.

Effective Drugs in Psychiatry: Magic Bullets or Hand Grenades?

Poster Presentation, 2nd World Conference on Magic Bullets, Nuremberg, Germany, October 5, 2008.

Diagnosis and Biological Treatment of Obsessive Compulsive Disorder

Obsessive Compulsive Foundation, Behavioral Therapy Institute, Chapel Hill, NC, October 15, 2008, October 1, 2011

Neuroscience 101.

Duke Clinical Research Institute. Conference Series. Durham, NC. September 15, 2008

An Introduction to Neuroscience Research.

American Medical Writers Association Conference. Chapel Hill, NC. May 7, 2010.

Safe Opioid Prescribing: A Clinical Challenge & A Public Health Opportunity

- North Carolina Governor's Institute for Substance Abuse. Southern Regional Area Health Education Center (SR AHEC) Office of Continuing Medical Education. Warsaw, NC November 15, 2010. Kinston, NC October 26, 2010. Wilson, NC June 23, 2010.
- Pain Medicine: What the Effective Case Manager Needs to Know
Continuing Educational Unit (CEU) Presentation
Case Management Society of America (CMSA) Spring Conference, Raleigh, NC March 4, 2011
- Pain Management in Psychiatric Settings
Continuing Medical Education (CME) series
Central Regional Hospital, Butner, NC February 1, 2011
Cherry Hospital, Goldsboro, NC February 8, 2011
- Pain Medicine and Opioid Prescribing: Standards of Care
Continuing Medical Education, Duke University CME
Triangle Family Practice, Durham, NC June 16, 2011
- Safe and Effective Pain Management
Sponsored by North Carolina Center for Excellence and North Carolina Governor's Institute for Substance Abuse, Carolina Family Health Center, Wilson, NC August 2, 2011
- Effective Pain Management and Safe Opioid Prescribing
Continuing Medical Education (CME), Sponsored by North Carolina Area L AHEC Program and North Carolina Governor's Institute for Substance Abuse, Halifax Regional Hospital, Roanoke Rapids, NC, November 1, 2011
- Tools for Practicing Safe and Effective Pain Medicine
Medical Staff Meeting, Sponsored by North Carolina Area L AHEC Program and North Carolina Governor's Institute for Substance Abuse, Lenoir Memorial Hospital, Kinston, NC, November 17, 2011
- Managing the Risks Associated with an Opioid Trial: Time-Efficient Strategies for Identifying, Monitoring, and Treating High-Risk Patients
International Conference on Opioids, Boston, MA, June 12, 2012
- Open Label Milnacipran for Persistent Pain after Total Knee Arthroplasty
Poster Presentation, 14th World Congress on Pain, International Association for the Study of Pain. Milan, Italy, August 30, 2012
- Chronic Pain, Safe Opioid Prescribing, and Standards of Care
Federally Qualified Healthcare Center (FQHC) Medical Director's Meeting
Raleigh, NC, January 30, 2013
- Pain Medicine Standards for the Primary Care Provider
Chronic Pain Initiative Training, Adult Wake Health Services providers
Raleigh, NC, February 7, 2013
- Assessing and Treating Chronic Pain in Clients At Risk of Substance Use Disorders
University of North Carolina School of Social Work, Chapel Hill, NC, Monday, April 21, 2014
- Project Lazarus, Chronic Pain Initiative
Pain Narrative for Primary Care Physicians Kenansville, NC October 24, 2013

Peer-Review Activities:

Reviewer, Primary Care Companion to the Journal of Clinical Psychiatry, 2008-present
Reviewer, General Hospital Psychiatry, 2009-present
Reviewer, Bioorganic & Medicinal Chemistry Letters, 2010-present
Reviewer, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2010-present
Reviewer, Clinical Journal of Pain, 2011-present
Reviewer, International Journal of Clinical Practice, 2012-present

Advisory Boards:

Bristol-Myers Squibb. *Atypical Antipsychotics: Sedation, Efficacy, and Long-term Functioning*. 2006
Shire Pharmaceuticals. *Extended Release Carbamazepine*. 2003
Journal of Clinical Psychiatry, Resident Advisory Board, 1998

Medical Monitoring Experience:

A Randomized, 6-week, Open-label Study Evaluating the Safety, Tolerability, and Efficacy of Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched from other Antipsychotic Agents (30 sites, 240 subjects); Sepracor. Duke Clinical Research Institute. 2010-2011.

A 24-week, Flexible-dose, Open-label, Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder; Sunovion. Duke Clinical Research Institute. 2010-2011

Principal Investigator Experience:

National Institute of Mental Health (NIMH) Sponsored:

*Co-principal Investigator
Treatment Units for Research on Neurocognition in Schizophrenia (TURNS). 2007-2008.*

Industry Sponsored:

Investigator-initiated:

Open-Label Milnacipran for Persistent Knee Pain One Year after Total Knee Arthroplasty (TKA). Forest Laboratories. 2009.

A Ten-Week, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Milnacipran for Radicular Pain Associated with Lumbosacral Disk Disease. Forest Laboratories. 2010

Sponsor-initiated (Multisite):

Pain/Analgesia

A Multicenter, Standard-of-Care-Controlled, Study to Evaluate the Long-Term Safety of Bicyclanil for the Treatment of Chronic Lower Back Pain: DOV. 2005

A Randomized, Double-Blind Study Comparing the Safety and Efficacy of the Lidocaine Patch 5% with Placebo in Patients with Pain from Carpal Tunnel Syndrome: ENDO Pharmaceuticals, Inc. 2006

Double-Blind, Randomized, Dose-Ranging, Parallel-Group Comparison of the Efficacy and Safety of Extended Release Tramadol Hydrochloride (Tramadol HCl ER) 100mg, 200 mg, and 300 mg, Celecoxib 200 mg, and Placebo in the Treatment of Osteoarthritis of the Knee: Biovail. 2002

Depression

A Twelve Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-Release (Wellbutrin XL, 150-450 mg/day) and Extended-Release Venlafaxine (Effexor XR, 75-225 mg/day) in Subjects with Major Depressive Disorder: GlaxoSmithKline. 2003

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Effects of Sexual Functioning of Extended-Release Bupropion Hydrochloride (300-450 mg) and Escitalopram (10-20 mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period: GlaxoSmithKline. 2004

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-week, Safety and Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects with Insomnia Related to Major Depression Disorder: Sepracor. 2004

A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK-0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder: Merck and Company. 2002

A Phase III, Double-Blind, Randomized, Prospective, Placebo-controlled, Multi-Site Trial Evaluating the Efficacy and Safety of up to and Including 2mg/day Adjunctive Risperidone versus Adjunctive Placebo in Subjects Undergoing Standard Treatment With Antidepressant Medication for Major Depressive Disorder: Janssen. 2005

A Phase IV, Double-blind, Placebo-controlled Study on the Efficacy of Lamotrigine as an Augmentation Agent in Treatment Refractory Unipolar Depression: GlaxoSmithKline. 2005

Insomnia

A 12 Month, Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicenter Long-term Safety Study of MK-0928 in the Treatment of Elderly Outpatients with Primary Insomnia: Merck. 2004

A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-groups Efficacy and Safety Extension Study of MK-0928 in the Treatment of Adult Outpatients with Primary Insomnia: Merck. 2004

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Adult Primary Insomnia Patients with Sleep Maintenance Difficulties: Neurocrine Biosciences Inc. 2002

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of a Modified Release Formulation of NBI-34060 in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties: Neurocrine Biosciences Inc. 2002

A Phase III, Open-Label, Outpatient Extension Study to Assess the Long-Term Safety of a Modified Release Formulation of NBI-34060 in Adult/Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties: Neurocrine Biosciences Inc. 2002

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Adults with Chronic Insomnia: Takeda Pharmaceuticals North America, Inc. 2002

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects with Chronic Insomnia: Takeda Pharmaceuticals North America, Inc. 2002

A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long-Term Administration of TAK-375 in Subjects with Chronic Insomnia: Takeda Pharmaceuticals North America, Inc. 2002

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment With Ramelteon in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data: Takeda. 2003

Bipolar Disorder

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing Aripiprazole with Placebo in Subjects with Bipolar I Disorder (Manic or Mixed) Requiring Inpatient Hospitalization: Bristol-Myers Squibb. 2005

A Phase III, Multicenter, Double-blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients with Bipolar I Disorder with a Major Depressive Episode: Bristol-Myers Squibb. 2005

A Phase III, Randomized, Placebo-Controlled, Double-blind Trial Evaluating the Safety and Efficacy of Sublingual Asenapine vs. Olanzapine and Placebo in Inpatients with an Acute Manic Episode: Organon/Pfizer. 2005

A Phase III, Three Week, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Safety and Efficacy Study of Extended-Release Carbamazepine in the Treatment of Bipolar I Disorder: Shire Pharmaceutical Development Inc. 2002

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Double-Dummy Trial of the Use of Quetiapine Fumarate (Seroquel) in the Treatment of Patients with Bipolar Depression: AstraZeneca. 2003

A Multicenter, Randomized, Parallel-Group, Double-Blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Tablets 400mg to 800mg Daily in Divided Doses) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients: AstraZeneca. 2003

Protocol for the Psychometric Validation of a Functional Status Questionnaire Designed for use in Bipolar Disorder: RTI. 2003

Case Controlled DNA/RNA/Serum/Plasma/Urine Banking Collection in Caucasians with Bipolar I Disorder: Precision Med. 2002

A Phase II, Randomized, Double-Blind Comparison of the Efficacy and Safety of Aripiprazole Intramuscular Formula, Lorazepam, or Placebo in the Treatment of Acutely Agitated Patients Diagnosed with Bipolar I Disorder, Manic or Mixed: Bristol-Myers Squibb. 2003

Schizophrenia

A Phase I, Open-label, Parallel, Randomized, Dose Proportionality Pharmacokinetic Study of Paliperidone After Intramuscular Injection of Paliperidone Palmitate in the Deltoid or Gluteal Muscle in Subjects with Schizophrenia: Johnson & Johnson. 2005

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating QT/QTc Intervals Following Administration of Extended-Release Paliperidone and Quetiapine in Subjects with Schizophrenia or Schizoaffective Disorder: Johnson & Johnson. 2006

A Randomized, Double-blind, Comparison of the Efficacy and Safety of Aripiprazole IM Formula, Haloperidol, or Placebo in the Treatment of Acutely Agitated Patients with a Diagnosis of Schizophrenia or Schizoaffective Disorder: Bristol-Myers Squibb. 2003

A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Paliperidone Palmitate in Subjects with Schizophrenia: Johnson & Johnson. 2004

A Phase IV, Randomized, Multicenter, Double-blind, Flexible-dosed, Parallel Study Comparing the Efficacy of Olanzapine with Quetiapine on Various Measures of Psychopathology, Quality of Life, Health Outcomes,

and Safety in Obese Outpatients Meeting Diagnostic Criteria for Schizophrenia or Schizoaffective Disorder: Eli Lilly. 2003

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of Donepezil Hydrochloride as Adjunctive Therapy in the Treatment of Cognitive Impairment in Patients with Schizophrenia or Schizoaffective Disorder: Pfizer, Inc. 2003

*Effect of Antipsychotic Therapy on Insulin Sensitivity: A Comparison of Olanzapine and Risperidone in Patients with Schizophrenia: Eli Lilly. 2005. **Coordinating Center Principal Investigator***

A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Evaluation of the Efficacy of a Flexible Dose of Lamotrigine versus Placebo as Add-On Therapy in Schizophrenia: GlaxoSmithKline. 2004

A 6-Week, Double-Blind, Randomized, Fixed-Dose, Parallel-Group Study of the Efficacy and Safety of Three Dose Levels of SM-13496 Compared to Placebo and Haloperidol in Patients with Schizophrenia Who are Experiencing an Acute Exacerbation of Symptoms: Sumitomo Pharmaceuticals America, Ltd. 2002

A Randomized, Open-Label, Dose-Blinded, Multicenter, 6-Month Study of Safety and Tolerability of 3 Dose Levels of SM-13496 in Patients with Schizophrenia: Sumitomo Pharmaceuticals America Ltd. 2002

A Randomized Double-Blind, Placebo-Controlled, Dose-Response Study of R209130 in Subjects with Schizophrenia Who Have Predominantly Negative Symptoms: Johnson & Johnson Pharmaceutical Research and Development. 2003

A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 2 Fixed Dosages of Extended Release OROS® Paliperidone (6 and 12 mg/day) and Olanzapine (10mg/day), With Open-Label Extension, in Treatment of Subjects With Schizophrenia: Johnson and Johnson. 2005

A Double-Blind, Randomized, Fixed-Dose, Placebo-Controlled, Parallel-Group, Six-Week Efficacy, Safety, and Tolerability Study of Two Dose Levels of SM-13496 in Patients with Schizophrenia by DSM-IV Criteria who are Experiencing an Acute Exacerbation of Symptoms: Sumitomo Pharmaceuticals America Ltd. 2004

A Phase III, Multicenter, Randomized, Double-Blind, Flexible-dose, 6-week Trial of the Efficacy and Safety of Asenapine Compared with Placebo Using Olanzapine Positive Control in Subjects with an Acute Exacerbation of Schizophrenia: Organon/Pfizer. 2005

A Phase II, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Ability of SGS518 to Improve Cognition in adults with Cognitive Impairment Associated with Schizophrenia: Saegis Pharmaceuticals. 2005

Anxiety Disorders

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Single-blind Placebo Lead-in Designed to Assess the Acute Effects of Duloxetine in the Treatment of Generalized Anxiety Disorder: Eli Lilly. 2004.

A Phase III, Multicenter, Randomized, Double-blind, Placebo and Comparator-controlled Study Designed to Assess the Acute Effects of Duloxetine Compared with Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder: Eli Lilly. 2005.

A Double-Blind, Randomized, Prospective Study to Evaluate Adjunctive Risperidone versus Adjunctive Placebo in Generalized Anxiety Disorder Suboptimally Responsive to Standard Psychotropic Therapy: Janssen. 2004

A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Adjunctive Therapy Trial Consisting of Subjects with Insomnia Related to Generalized Anxiety Disorder Who Will be Treated for 10 Weeks with Open-label Escitalopram Oxalate at Bedtime, and Randomized to Receive Either Eszopiclone or Placebo nightly for 8 weeks: Sepracor. 2005

A Randomized, Double-Blind, Placebo-Controlled Study of Xanax XR in the Treatment of Adolescents with a Primary Diagnosis of Panic Disorder A6131002: Pfizer. 2003

A Randomized, Double-Blind, Placebo-Controlled Study of Continuation Treatment with Xanax XR in the Treatment of Adolescents with a Primary Diagnosis of Panic Disorder A6131007: Pfizer. 2003

An Open-Label Study to Assess the Safety and Tolerability of Xanax XR in the Treatment of Adolescents with Panic Disorder or Anxiety with Panic Attacks A6131004: Pfizer. 2003

A Phase II, Twelve Week, Double-Blind and Placebo-Controlled Study to Evaluate the Safety and Efficacy of Two Doses of CP-448,187 (1.5mg and 3.0mg) in Subjects with Obsessive Compulsive Disorder: Pfizer, Inc. 2002

Attention Deficit Hyperactivity Disorder

A Phase III, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Safety and Efficacy Study of SPD503 in Children and Adolescents Aged 6-17 with Attention Deficit Hyperactivity Disorder (ADHD): Shire. 2003

A Phase II, Open-label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 with Attention-Deficit Hyperactivity Disorder (ADHD): Shire. 2004

A Phase III, Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study of NRP104 in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD): New River Pharmaceuticals. 2004

A Phase III, Long-Term, Open-Label, and Single-Arm Study of NRP104 Daily in Children Aged 6-12 Years with Attention Deficit Hyperactivity Disorder (ADHD): New River Pharmaceuticals. 2004

Dementia/Cognitive Impairment

A Phase II Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled, Multicenter, Safety and Efficacy Evaluation of Three Doses of NS 2330 in Patients with Mild to Moderate Dementia of the Alzheimer's Type: Boehringer Ingelheim. 2003

A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Subjects with Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Probable Alzheimer's Disease: Janssen Research Foundation. 2001

A Phase IV, One-year, Multi-center, Randomized, Double-blind, Placebo-controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects with Mild Cognitive Impairment: Pfizer/Eisai. 2004

Pathological Gambling

Nalmefene in the Treatment of Pathological Gambling. A Placebo-Controlled Dose-Response Study: Oy Contral Pharma Ltd. 2002.

A Phase II, Randomized, Double-Blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Nalmefene HCL in the Treatment of Pathological Gambling: Somaxon. 2005.